Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
University of Utah
With
National Heart, Lung, and Blood Institute (NHLBI)
Pediatric Heart Network
BACKGROUND:
MR causes volume overload and hemodynamic burden on the left ventricle. Initial compensatory mechanisms may fail, leading to increased severity. Patients who have had repair of an atrioventricular septal defect (AVSD) are selected for this study as they have a relatively high incidence of moderate MR and their regurgitant orifice is mobile and dynamic, contributing to the likelihood that they might respond to medical therapy.
DESIGN NARRATIVE:
This is a randomized, double-blind, placebo-controlled trial of ACE-I therapy in children less than 18 years of age with at least moderate MR who are at least 6 months postoperative from repair of an AVSD. A non-randomized Observational Phase enrolled 181 children who were less than 6 months postoperative from repair of an AVSD, who were then evaluated at 6 months for trial eligibility.
Age
0–18
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Children less than 18 years of age and at least 6 months post AVSD repair or reoperation
At least moderate MR
Asymptomatic or minimally symptomatic, defined by Ross Heart Failure Class I or II
Atrioventricular synchrony (paced or intrinsic)
You may not be if
Tetrology of Fallot, total or partial anomalous venous connection